BiovaxID lymphoma vaccine to be featured at ASH Meeting

Nov 16 2010NewsGuard 100/100 Score

Biovest International, Inc. (OTCQB: BVTI) today announced that BiovaxID®, Biovest's personalized lymphoma vaccine, will be featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Monday, December 6th in Orlando, Florida.

“Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration in Follicular Lymphoma Patients.”

Stephen J. Schuster, M.D., Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, will deliver the BiovaxID presentation titled, "Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration in Follicular Lymphoma Patients."

The abstract can be accessed at the ASH website by visiting: http://ash.confex.com/ash/2010/webprogram/Paper34600.html

Source:

Biovest International, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Thrombotic thrombocytopenic purpura cases after CoronaVac raise concerns over vaccine safety
New nasal vaccine could help stop the spread of whooping cough
New vaccine shows potential in preventing recurrence of triple-negative breast cancer
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine
Public trust in COVID-19 vaccine science influences vaccine uptake in the US
Early RSV vaccination in pregnancy provides best protection for newborns
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17
WHO grants Emergency Use Listing for LC16m8 mpox vaccine

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Argonne receives $21.7 million to advance cancer and vaccine discoveries